Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder.
aquaporin (AQP) 4
autoantibody
autoimmunity
central nervous system
complement
factor H
inflammation
neuromyelitis optica spectrum disorder
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
01
2021
accepted:
31
03
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system (CNS), characterized by pathogenic, complement-activating autoantibodies against the main water channel in the CNS, aquaporin 4 (AQP4). NMOSD is frequently associated with additional autoantibodies and antibody-mediated diseases. Because the alternative pathway amplifies complement activation, our aim was to evaluate the presence of autoantibodies against the alternative pathway C3 convertase, its components C3b and factor B, and the complement regulator factor H (FH) in NMOSD. Four out of 45 AQP4-seropositive NMOSD patients (~9%) had FH autoantibodies in serum and none had antibodies to C3b, factor B and C3bBb. The FH autoantibody titers were low in three and high in one of the patients, and the avidity indexes were low. FH-IgG complexes were detected in the purified IgG fractions by Western blot. The autoantibodies bound to FH domains 19-20, and also recognized the homologous FH-related protein 1 (FHR-1), similar to FH autoantibodies associated with atypical hemolytic uremic syndrome (aHUS). However, in contrast to the majority of autoantibody-positive aHUS patients, these four NMOSD patients did not lack FHR-1. Analysis of autoantibody binding to FH19-20 mutants and linear synthetic peptides of the C-terminal FH and FHR-1 domains, as well as reduced FH, revealed differences in the exact binding sites of the autoantibodies. Importantly, all four autoantibodies inhibited C3b binding to FH. In conclusion, our results demonstrate that FH autoantibodies are not uncommon in NMOSD and suggest that generation of antibodies against complement regulating factors among other autoantibodies may contribute to the complement-mediated damage in NMOSD.
Identifiants
pubmed: 33986750
doi: 10.3389/fimmu.2021.660382
pmc: PMC8111293
doi:
Substances chimiques
Autoantibodies
0
Blood Proteins
0
Immunoglobulin G
0
factor H-related protein 1
0
Complement C3b
80295-43-8
Complement Factor H
80295-65-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
660382Informations de copyright
Copyright © 2021 Uzonyi, Szabó, Trojnár, Hyvärinen, Uray, Nielsen, Erdei, Jokiranta, Prohászka, Illes and Józsi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2010 Aug;47(13):2187-97
pubmed: 20580090
Mol Immunol. 2016 Feb;70:47-55
pubmed: 26703217
Acta Neuropathol Commun. 2017 Jul 27;5(1):57
pubmed: 28750658
Mol Immunol. 2009 May;46(8-9):1573-94
pubmed: 19297022
Int Immunol. 2003 Oct;15(10):1229-36
pubmed: 13679392
Immunobiology. 2012 Nov;217(11):1057-66
pubmed: 22964231
J Proteome Res. 2016 Feb 5;15(2):659-66
pubmed: 26759122
J Exp Med. 2005 Aug 15;202(4):473-7
pubmed: 16087714
Neurology. 2021 Jan 12;96(2):59-77
pubmed: 33310876
Arthritis Res Ther. 2012 Aug 15;14(4):R185
pubmed: 22894814
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):922-30
pubmed: 23142960
Immunobiology. 2012 Nov;217(11):1034-46
pubmed: 22964229
Blood. 2007 Sep 1;110(5):1516-8
pubmed: 17495132
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
J Am Soc Nephrol. 2017 May;28(5):1603-1613
pubmed: 28096309
Mol Immunol. 2006 Jan;43(1-2):97-106
pubmed: 16026839
Front Immunol. 2015 May 26;6:257
pubmed: 26074922
Ann Neurol. 2016 May;79(5):794-805
pubmed: 26946517
Mol Immunol. 2013 Dec 15;56(3):213-21
pubmed: 23790637
Blood. 2008 Feb 1;111(3):1512-4
pubmed: 18006700
Nat Struct Mol Biol. 2011 Apr;18(4):463-70
pubmed: 21317894
Eur J Neurol. 2010 Aug;17(8):1019-32
pubmed: 20528913
J Biol Chem. 2015 Apr 10;290(15):9500-10
pubmed: 25659429
Cell Stress Chaperones. 2012 Mar;17(2):215-27
pubmed: 22038196
Cancer Immunol Res. 2015 Dec;3(12):1325-32
pubmed: 26216416
Clin Exp Immunol. 2006 May;144(2):342-52
pubmed: 16634809
Biomolecules. 2012 Feb 07;2(1):46-75
pubmed: 24970127
Mult Scler. 2015 Nov;21(13):1644-54
pubmed: 25698168
Semin Thromb Hemost. 2014 Jun;40(4):431-43
pubmed: 24799303
Clin Exp Immunol. 2014 May;176(2):149-64
pubmed: 24666204
J Rheumatol. 2015 Oct;42(10):1786-93
pubmed: 26276971
Mol Immunol. 2014 Feb;57(2):200-9
pubmed: 24172223
J Neurol. 2020 Oct 3;:
pubmed: 33011853
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Mol Immunol. 2011 Aug;48(14):1656-65
pubmed: 21757235
J Infect Dis. 2012 Mar 15;205(6):995-1004
pubmed: 22291192
Mult Scler. 2017 Jun;23(7):946-955
pubmed: 27613120
Kidney Int. 2012 Nov;82(10):1084-92
pubmed: 22854646
Science. 1969 Apr 25;164(3878):436-7
pubmed: 4180576
Brain. 2007 May;130(Pt 5):1194-205
pubmed: 17282996
Clin Cancer Res. 2010 Jun 15;16(12):3226-31
pubmed: 20515868
Eur J Neurol. 2013 Nov;20(11):1492-5
pubmed: 23293933
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
Brain. 2007 May;130(Pt 5):1224-34
pubmed: 17405762
Immunol Lett. 2014 Aug;160(2):163-71
pubmed: 24491679
Expert Rev Neurother. 2017 Jun;17(6):579-591
pubmed: 28092989
Brain Pathol. 2014 Jan;24(1):74-82
pubmed: 24345221
PLoS One. 2015 Oct 13;10(10):e0139659
pubmed: 26460890
FEBS Lett. 2016 Aug;590(15):2418-34
pubmed: 27393384
Lancet. 2004 Dec 11-17;364(9451):2106-12
pubmed: 15589308
Expert Opin Biol Ther. 2021 Feb 16;:1-14
pubmed: 33513036
Mol Immunol. 2010 Apr;47(7-8):1476-83
pubmed: 20193965
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
J Neuroimmunol. 2014 Sep 15;274(1-2):185-91
pubmed: 25109258
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2897-902
pubmed: 21285368
Mult Scler. 2016 Aug;22(9):1192-201
pubmed: 26514978
J Med Genet. 2009 Jul;46(7):447-50
pubmed: 19435718
Proc Natl Acad Sci U S A. 1984 Jul;81(13):3998-4002
pubmed: 6204335
Arch Neurol. 2008 Jan;65(1):78-83
pubmed: 18195142
Gene. 1995 Sep 11;162(2):225-9
pubmed: 7557433
Arch Neurol. 2010 Oct;67(10):1201-8
pubmed: 20937947
J Am Soc Nephrol. 2005 Feb;16(2):555-63
pubmed: 15590760
J Exp Med. 1992 Apr 1;175(4):939-50
pubmed: 1532415
Biochem J. 1998 Apr 1;331 ( Pt 1):41-7
pubmed: 9512460
Mol Immunol. 2007 Apr;44(10):2697-706
pubmed: 17208302
J Biol Chem. 2015 Oct 16;290(42):25343-55
pubmed: 26245903
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Blood. 2010 Jan 14;115(2):379-87
pubmed: 19861685
Front Immunol. 2017 Mar 30;8:302
pubmed: 28424685
Kidney Int. 2011 Aug;80(4):397-404
pubmed: 21677636
Mult Scler. 2011 Sep;17(9):1067-73
pubmed: 21543553
Ann Rheum Dis. 2011 Feb;70(2):373-9
pubmed: 21068094